15
Participants
Start Date
September 30, 2000
Primary Completion Date
August 31, 2005
Study Completion Date
August 31, 2005
5-Flourouracil, Interferon-a, IL-2 and Thalidomide
"Patients will receive oral dosages of Thalidomide at 200mg/day to start, with dosage gradually increasing up to a max of 1200mg/day. This will be taken in combination with:5-fluorouracil, given by continuous IV infusion over 24 hours (Day 1) every week for 4 weeks.~Interferon-α, given subcutaneously on Day 1, 3 and 5 of every week for 4 weeks. Interleukin-2, given by continuous IV infusion Days 2-5, every week for 4 weeks.~Treatment will be followed by 2 weeks of rest then repeated."
Lovelace Sandia Health Systems Dept of Hematology, Albuquerque
University of New Mexico, Albuquerque
New Mexico Cancer Care Associates, Santa Fe
New Mexico Cancer Research Alliance
OTHER